NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Setting aside other factors, it appears the DCvax-L trial will probably have approximately 150% MORE TOTAL SURVIVORS at a somewhat similar or more mature time than the Optune trial did.

IMHO. See full text: https://jamanetwork.com/journals/jama/article-abstract/2666504?redirect=true

From my perspective, the age of the DCVax-L trial since initiation, median enrollment and last patient enrolled are already more mature than Optune's "final" longterm follow up analysis. (Optune's longterm "final" data cutoff was December 2016. Of course, the Optune trial was unblinded from beginning to end.)


(Note: Moreover, DCVax-L is a blinded trial.)